title: Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans.
abstract: BACKGROUND
  Glucagon-like peptide-1(7-36)amide (GLP-1) retards gastric emptying, reduces food intake, and inhibits antroduodenal and stimulates pyloric motility.
  
  
  OBJECTIVE
  To assess the effects of synthetic GLP-1 on fundus tone and volume waves, gastric compliance, and perception of gastric distension.
  
  
  METHODS
  Eleven healthy male volunteers.
  
  
  METHODS
  Background infusions were saline, or GLP-1 at 0.3 or 0.9 pmol/ kg/min on separate days in random order. Interdigestive fundus motility was recorded by barostat (maximum capacity of intragastric bag 1200 ml) during basal and peptide periods of 60 minutes each. Thereafter stepwise isobaric distensions were performed with ongoing peptide infusion, and gastric sensation was scored.
  
  
  RESULTS
  Low and high loads of GLP-1 induced physiological and supraphysiological plasma immunoreactivities, respectively. GLP-1 dose dependently diminished fundus tone (162.9 (15.0) and 259.5 (17.2) v 121.1 (6.0) ml with saline; p<0.0001). It greatly reduced volume waves and total volume displaced by these events (p<0.0001). Gastric compliance derived from isobaric distension rose in a dose related manner (42.6 (5.5) and 63.6 (7.7) v 27.0 (3.5) ml/mm Hg; p=0.0004) with a concomitant reduction of the pressure at half maximum bag volume (6.4 (0.4) and 5.5 (0.4) v 7.2 (0.1) mm Hg; p<0.0001). GLP-1 did not change perception of isobaric distension but reduced the perception score related to corresponding bag volume (p<0.0001).
  
  
  CONCLUSIONS
  GLP-1 is a candidate physiological inhibitory regulator of fundus motility. It allows the stomach to afford a larger volume without increase in sensation.
authors.affiliation: Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Schirra
authors.forename: U
authors.initials: U
authors.lastname: Wank
authors.forename: R
authors.initials: R
authors.lastname: Arnold
authors.forename: B
authors.initials: B
authors.lastname: Göke
authors.forename: M
authors.initials: M
authors.lastname: Katschinski
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D005746:Gastric Emptying / Q000187:drug effects*; D005748:Gastric Fundus / Q000187:drug effects / Q000502:physiology; D005768:Gastrointestinal Hormones / Q000097:blood; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D006801:Humans; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology*; D011312:Pressure; D012528:Satiety Response / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D005768:Gastrointestinal Hormones; D010446:Peptide Fragments; C055453:glucagon-like peptide 1 (7-36)amide; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon